Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue 1, 2015, Pages

  Bostwick, A Doran ^a   Salama, April K ^a   Hanks, Brent A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Advanced melanoma; Autoimmunity; Ipilimumab; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CHLORPHENIRAMINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENOSUMAB; HYDROCODONE; HYDROCORTISONE; INFLIXIMAB; IPILIMUMAB; METHYLPREDNISOLONE; MOMETASONE FUROATE; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY;

ACUTE ABDOMEN; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CASE REPORT; COLITIS; COLON PERFORATION; COLON RESECTION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COUGHING; DISEASE COURSE; HUMAN; HYPOPITUITARISM; INTESTINE ULCER; MALE; MANUBRIUM; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROTIDECTOMY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; RECTUM POLYP; TOTAL COLON RESECTION; TRACHEOBRONCHITIS; TREATMENT RESPONSE; ULCERATIVE COLITIS; VERTEBRA BODY;

EID: 84997610273     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-015-0064-2     Document Type: Article

References (15)

1. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. 2009;58:823-30.
2. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206:1717-25.
3. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210:1695-710.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-23.
5. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-7.
6. Callahan MK, Postow MA, Wolchok JD. Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol. 2013;31:191-9.
7. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043-53.
8. Kyi C, Carvajal RD, Wolchok JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer. 2014;2:1-4.
9. Pedersen M, Andersen R, Norgaard P, Jacobsen S, Thielson P, Thor Straten P, et al. Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother 2014;63:1341-6.
10. Kar S, Thomas SG. A case of tracheobronchitis in ulcerative colitis: a review of literature. Clin Respir J. 2009;3:51-4.
11. Bayraktaroglu S, Basoglu O, Ceylan N, Aydin A, Tuncel S, Savas R. A rare extraintestinal manifestation of ulcerative colitis: tracheobronchitis associated with ulcerative colitis. J Crohns Colitis. 2010;4:679-82.
12. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039-47.
13. Scarpati GDV, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, et al. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther. 2014;7:203-9.
14. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010;37:473-84.
15. Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut. 2013;62:1795-805.